How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,190 results for

Benign Prostatic Hyperplasia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

22. Lower Urinary Tract Symptoms-Suspicion of Benign Prostatic Hyperplasia

Lower Urinary Tract Symptoms-Suspicion of Benign Prostatic Hyperplasia Date of origin: 1995 Last review date: 2014 ACR Appropriateness Criteria ® 1 Lower Urinary Tract Symptoms: Suspicion of BPH American College of Radiology ACR Appropriateness Criteria ® Clinical Condition: Lower Urinary Tract Symptoms: Suspicion of Benign Prostatic Hyperplasia Radiologic Procedure Rating Comments RRL* US pelvis (bladder and prostate) transabdominal 6 Consider this procedure after patient voids to measure (...) without IV contrast 1 ???? CT abdomen and pelvis with IV contrast 1 ???? Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate *Relative Radiation Level ACR Appropriateness Criteria ® 2 Lower Urinary Tract Symptoms: Suspicion of BPH LOWER URINARY TRACT SYMPTOMS: SUSPICION OF BENIGN PROSTATIC HYPERPLASIA Expert Panel on Urologic Imaging: Barak Friedman, MD 1 ; John R. Leyendecker, MD 2 ; M. Donald Blaufox, MD, PhD 3 ; Steven C. Eberhardt, MD 4 ; Pat F. Fulgham

2019 American College of Radiology

23. Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia

Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia CUAJ • October 2018 • Volume 12, Issue 10 © 2018 Canadian Urological Association 303 ORIGINAL RESEARCH CUA GUIDELINE Cite as: Can Urol Assoc J 2018;12(10):303-12. http://dx.doi.org/10.5489/cuaj.5616 Introduction The current document summarizes the state-of-the-art know- ledge as it relates to management of male lower urinary tract symptoms (MLUTS) secondary to benign prostatic hyper (...) ; Kevin C. Zorn, MD 5 1 Department of Urology, Queen’s University, Kingston, ON; 2 Service d’Urologie and Centre de la Prostate, Longueuil, QC; 3 Division of Urology, University of Toronto, Humber River Hospital, Toronto, ON; 4 Division of Urology, University of Toronto, Toronto, ON; 5 Université de Montréal, Montreal, QC; Canada Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 updateCUAJ • October 2018 • Volume 12, Issue 10

2018 Canadian Urological Association

24. Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. (Full text)

Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. A variety of alpha-blockers are used for treating lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). Silodosin is a novel, more selective alpha-blocker, which is specific to the lower urinary tract and may have fewer side effects than other alpha-blockers.To assess the effects of silodosin for the treatment of LUTS in men with BPH.We performed a comprehensive (...) analyses using a random-effects model and interpreted them according to the Cochrane Handbook for Systematic Reviews of Interventions. We rated the quality of evidence according to the GRADE approach.We included 19 unique studies with 4295 randomized participants across four comparisons for short-term follow-up. The mean age, prostate volume, and International Prostate Symptom Score were 66.5 years, 38.2 mL, and 19.1, respectively. Silodosin versus placeboBased on four studies with a total of 1968

2017 Cochrane PubMed abstract

25. Prostate artery embolisation for benign prostatic hyperplasia

Prostate artery embolisation for benign prostatic hyperplasia Prostate artery embolisation for benign prostatic hyperplasia Prostate artery embolisation for benign prostatic hyperplasia Vreugdenburg T, Wild C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Vreugdenburg T, Wild C. Prostate artery embolisation for benign prostatic (...) commonly reported side effects associated with PAE in all studies were minor. Currently, five RCTs are ongoing comparing PAE to TURP, the end of which is scheduled for February 2021. A new evaluation is proposed in the year 2021, if results from RCTs are available by then. Project page URL Final publication URL Additional data URL Indexing Status Subject indexing assigned by CRD MeSH Arteries; Embolization, Therapeutic; Humans; Male; Prostate-Specific Antigen; Prostatic Hyperplasia Language Published

2017 Health Technology Assessment (HTA) Database.

26. Prostate artery embolisation for benign prostatic hyperplasia. Decision Support Document 105.

Prostate artery embolisation for benign prostatic hyperplasia. Decision Support Document 105. Prostate artery embolisation for benign prostatic hyperplasia - Repository of AIHTA GmbH English | Browse - - - Prostate artery embolisation for benign prostatic hyperplasia Vreugdenburg, Thomas and Wild, C. (2017): Prostate artery embolisation for benign prostatic hyperplasia. Decision Support Document 105. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 933kB (...) . A new evaluation is proposed in the year 2021, if results from RCTs are available. Item Type: Decision Support Document Keywords: Benign prostatic hyperplasia (BPH), lower urinary tract symptoms (LUTS), prostate artery embolisation (PAE) Subjects: > > > > > Language: English Series Name: Decision Support Document 105 Deposited on: 17 Jul 2017 10:05 Last Modified: 15 Jul 2020 17:56 Repository Staff Only: © Copyright ,

2017 Austrian Institute of Health Technology Assessment

27. Randomised Clinical Trial of Prostatic Artery Embolisation Versus a Sham Procedure for Benign Prostatic Hyperplasia (Full text)

Randomised Clinical Trial of Prostatic Artery Embolisation Versus a Sham Procedure for Benign Prostatic Hyperplasia Prostatic artery embolisation (PAE) has been associated with an improvement of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH), but conclusive evidence of efficacy from randomised controlled clinical trials has been lacking.To assess the safety and efficacy of PAE compared with a sham procedure in the treatment of LUTS/BPH.A randomised, single (...) associated with benign prostatic hyperplasia.Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.

2020 EvidenceUpdates PubMed abstract

28. Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia

Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia 1 Purpose Benign prostatic hyperplasia (BPH) is a histologic diagnosis that refers to the proliferation of smooth muscle and epithelial cells within the prostatic transition zone. The prevalence and the severity of lower urinary tract symptoms (LUTS) in the aging male can be progressive and is an important diagnosis in the healthcare of patients and the welfare of society. In the management (...) . magnetic resonance imaging [MRI]/ computed tomography [CT]) prior to surgical intervention for LUTS attributed to BPH. (Clinical Principle) Approved by the AUA Board of Directors May 2018 Authors’ disclosure of po- tential conflicts of interest and author/staff contribu- tions appear at the end of the article. © 2018 by the American Urological Association American Urological Association (AUA) Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE

2018 American Urological Association

29. Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for benign prostatic hyperplasia

Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for benign prostatic hyperplasia '); } else { document.write(' '); } ACE | Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for benign prostatic hyperplasia Search > > Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for benign prostatic hyperplasia - Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for the treatment of benign prostatic hyperplasia (...) Published on 2 July 2018 Guidance Recommendations The Ministry of Health's Drug Advisory Committee has recommended: Alfuzosin 10mg tablet for the treatment of benign prostatic hyperplasia. Subsidy status Alfuzosin 10mg tablet is recommended for inclusion on the MOH Standard Drug List (SDL). SDL subsidy does not apply to tamsulosin 0.4mg tablet, dutasteride 0.5mg capsule or dutasteride 0.5mg/tamsulosin 0.4mg capsule. Factors considered to inform the recommendations for subsidy Technology evaluation Point

2018 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

30. Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia (IPG475)

Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia (IPG475) Overview | Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia | Guidance | NICE Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia Interventional procedures guidance [IPG475] Published date: January 2014 Share Save (...) Guidance The National Institute for Health and Care Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia, in January 2014. Description Benign prostatic hyperplasia (BPH) is a common condition that affects older men. It is characterised by an increase in the size of the prostate, which is caused by an increased number

2014 National Institute for Health and Clinical Excellence - Interventional Procedures

31. UroLift System (NeoTract Inc.) for treatment of benign prostatic hyperplasia

UroLift System (NeoTract Inc.) for treatment of benign prostatic hyperplasia UroLift System (NeoTract Inc.) for treatment of benign prostatic hyperplasia UroLift System (NeoTract Inc.) for treatment of benign prostatic hyperplasia HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. UroLift System (NeoTract Inc.) for treatment of benign (...) prostatic hyperplasia. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2016 Authors' objectives Current surgical treatment of benign prostatic hyperplasia (BPH) involves a transurethral resection of the prostate (TURP) requiring general or spinal anesthesia and inpatient hospitalization. TURP is associated with measureable complications, including sexual dysfunction, ejaculatory dysfunction, erectile dysfunction, urinary incontinence, bladder neck contractures, urethral stricture

2017 Health Technology Assessment (HTA) Database.

32. [Diode laser vaporization in benign prostatic hyperplasia]

[Diode laser vaporization in benign prostatic hyperplasia] [Diode laser vaporization in benign prostatic hyperplasia] [Diode laser vaporization in benign prostatic hyperplasia] Virgilio S, Alcaraz A, Pichon-Riviere A, Augustovski F,García Martí S, Bardach A, Ciapponi A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Virgilio S, Alcaraz (...) A, Pichon-Riviere A, Augustovski F,García Martí S, Bardach A, Ciapponi A. [Diode laser vaporization in benign prostatic hyperplasia] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rapida No 531. 2017 Authors' conclusions Evidence of moderate quality showed that in patients with a prostate volume of less than or equal to 80 mL, diode laser vaporization when compared with other surgical techniques

2017 Health Technology Assessment (HTA) Database.

33. Urolift system (NeoTract Inc.) for treatment of benign prostatic hyperplasia

Urolift system (NeoTract Inc.) for treatment of benign prostatic hyperplasia Urolift system (NeoTract Inc.) for treatment of benign prostatic hyperplasia Urolift system (NeoTract Inc.) for treatment of benign prostatic hyperplasia HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Urolift system (NeoTract Inc.) for treatment of benign (...) prostatic hyperplasia. Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2017 Authors' conclusions Health Problem: Benign prostatic hyperplasia (BPH) is an enlargement or growth of the prostate that affects approximately 8 million men in the United States, including 30% of men older than 50 years of age and nearly 70% of men older than 70 years of age. The enlarged prostate restricts the urethra and applies pressure on the base of the bladder. This restriction of the urethra can result

2017 Health Technology Assessment (HTA) Database.

34. Prostate artery embolisation for benign prostatic hyperplasia (IPG453)

Prostate artery embolisation for benign prostatic hyperplasia (IPG453) Prostate artery embolisation for benign prostatic hyperplasia | Guidance | NICE Prostate artery embolisation for benign prostatic hyperplasia Interventional procedures guidance [IPG453] Published date: April 2013 Guidance This guidance has been updated and replaced by . Explore © NICE [year]. All rights reserved. Subject to .

2013 National Institute for Health and Clinical Excellence - Interventional Procedures

35. Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. (Full text)

Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. To compare prostatic artery embolisation (PAE) with transurethral resection of the prostate (TURP) in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia in terms of patient reported and functional outcomes.Randomised, open label, non-inferiority trial.Urology and radiology (...) departments of a Swiss tertiary care centre.103 patients aged ≥40 years with refractory lower urinary tract symptoms secondary to benign prostatic hyperplasia were randomised between 11 February 2014 and 24 May 2017; 48 and 51 patients reached the primary endpoint 12 weeks after PAE and TURP, respectively.PAE performed with 250-400 μm microspheres under local anaesthesia versus monopolar TURP performed under spinal or general anaesthesia.Primary outcome was change in international prostate symptoms score

2018 BMJ Controlled trial quality: predicted high PubMed abstract

36. Correlation between Prostatitis, Benign Prostatic Hyperplasia and Prostate Cancer: A systematic review and Meta-analysis. (Full text)

Correlation between Prostatitis, Benign Prostatic Hyperplasia and Prostate Cancer: A systematic review and Meta-analysis. Background: No consensus has been reached on the definite associations among prostatitis, benign prostatic hyperplasia (BPH) and prostate cancer (PCa). Hence, this meta-analysis was conducted to explore their triadic relation by summarizing epidemiological evidence. Methods: Systematical and comprehensive retrieval of online databases PubMed, PMC, EMBASE and Web of Science (...) was performed to acquire eligible studies, up to April 1st, 2019. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to clarify their correlations. Results: A total of 42 studies were enrolled in the quality assessment and 35 were finally included in the meta-analyses. Among them, 27 studies were included to describe the association between prostatitis and PCa (OR=1.72, 95% CI=1.44-2.06, I2 =90.1%, P<0.001). 21 studies presented significant evidence about the relation between BPH

2020 Journal of Cancer PubMed abstract

37. Prostatic Artery Embolization in Nonindex Benign Prostatic Hyperplasia Patients: Single-center Outcomes for Urinary Retention and Gross Prostatic Hematuria. (Abstract)

Prostatic Artery Embolization in Nonindex Benign Prostatic Hyperplasia Patients: Single-center Outcomes for Urinary Retention and Gross Prostatic Hematuria. To present outcomes for prostatic artery embolization (PAE) to treat urinary retention and gross prostatic hematuria in nonindex benign prostatic hyperplasia patients.Seventy-five patients undergoing PAE from December 2013 to August 2018 (age = 77.5 ± 8.6, age-adjusted Charlson comorbidity index = 4.6 ± 2.0, prostate volume = 224 mL ± 135 (...) thereafter. Subsequently, 13/16(81%) remained hematuria-free at 500 ± 501 days; 2/16(13%) required fulguration; 1/16(6%) developed bladder tumor. There were 2 deaths <30 days post-PAE, and 8(11%) Grade-II urinary infections.PAE provided safe, effective, and durable treatment for retention and gross hematuria in nonindex benign prostatic hyperplasia patients.Copyright © 2019 Elsevier Inc. All rights reserved.

2020 Urology

38. Meta-analysis and systematic review of intermediate-term follow-up of prostatic urethral lift for benign prostatic hyperplasia. (Abstract)

Meta-analysis and systematic review of intermediate-term follow-up of prostatic urethral lift for benign prostatic hyperplasia. Prostatic urethral lift (PUL), is a relatively new minimally invasive procedure for treatment of benign prostatic hyperplasia (BPH).This article is a systematic review and meta-analysis of all the articles published including follow-up of at least 24 months to analyze sustainability of results.We performed a critical review in according to the preferred reporting items (...) are grouped as group A and non-randomized studies as group B. At 24 months, the mean reduction in International Prostate Symptom Score (IPSS) from baseline was 9.1 in group A and 10.4 in group B. The mean improvement in peak flow rate (Qmax) was 3.7 mL/s in group A and 3 mL/s in group B, and quality of life (QoL) improved by 2.2 in both groups.PUL is a well-tolerated, minimally invasive therapy for BPH that provides favorable and durable symptomatic, sexual health, and functional outcomes up to 24 months

2020 International urology and nephrology

39. Holmium laser enucleation of the prostate in benign prostate hyperplasia patients with or without oral antithrombotic drugs: a meta-analysis. (Abstract)

Holmium laser enucleation of the prostate in benign prostate hyperplasia patients with or without oral antithrombotic drugs: a meta-analysis. The continuous intake of antithrombotic drugs during holmium laser enucleation of the prostate (HoLEP) remains nonconsensual. We aim to pool those controversial evidence and provide practical guidance of oral antithrombotics on HoLEP for benign prostate hyperplasia (BPH).PubMed, Embase and CENTRAL database were systematically searched up to June 2019

2020 International urology and nephrology

40. Enucleation of the prostate for benign prostatic hyperplasia thulium laser versus holmium laser: a systematic review and meta-analysis. (Abstract)

Enucleation of the prostate for benign prostatic hyperplasia thulium laser versus holmium laser: a systematic review and meta-analysis. To evaluate the clinical efficacy and safety of thulium laser vapoenucleation/enucleation of the prostate (ThuEP) versus holmium laser enucleation of the prostate (HoLEP) in the management of benign prostatic hyperplasia (BPH). A systematic literature search was performed using PubMed, Embase, and Web of Science to identify eligible studies published before

2020 Lasers in medical science

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>